Option And License Agreement Sample Contracts

Arcus Biosciences, Inc. – Amendment No. 1 to Option and License Agreement (November 8th, 2018)

This Amendment No. 1 to the Option and License Agreement (this "Amendment") is made and entered into effective as of September 1, 2018 (the "Amendment Effective Date") by and between Arcus Biosciences, Inc., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. ("Arcus"), and TAIHO Pharmaceutical Co., Ltd., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan ("TAIHO"). Arcus and TAIHO are sometimes collectively referred to herein as the "Parties" and separately as a "Party." Capitalized terms used herein but not defined herein shall have the meaning set forth in that certain Option and License Agreement made and entered into effective as of September 19, 2017, by and between Arcus and TAIHO (the "Agreement").

Avalanche Biotechnologies, Inc. – Second Amendment to Collaboration, Option and License Agreement (August 8th, 2018)

This Second Amendment ("Second Amendment") is entered into as of June 5, 2018 (the "Second Amendment Effective Date"), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O'Brien Drive, Menlo Park, CA 94025 ("Adverum"), and Editas Medicine, Inc., a Delaware corporation having an address at 11 Hurley St., Cambridge, MA 02141 ("Editas"), and amends that certain Collaboration, Option and License Agreement, dated August 8, 2016, by and between Adverum and Editas, as amended by that certain Amendment to Collaboration, Option and License Agreement, dated January 25, 2018 (the "Agreement"). Adverum and Editas may be referred to herein individually as a "Party" and collectively as the "Parties."

Isis Pharmaceuticals, Inc. – New Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc. And Biogen MA Inc. (August 7th, 2018)

This NEW STRATEGIC NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into as of the 19th day of April, 2018 (the "Execution Date") by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 ("Ionis"), and Biogen MA Inc., a Massachusetts corporation, having its principal place of business at 225 Binney Street, Cambridge, MA 02142 ("Biogen"). Biogen and Ionis each may be referred to herein individually as a "Party" or collectively as the "Parties." Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.

Magenta Therapeutics, Inc. – EXCLUSIVE RESEARCH, DEVELOPMENT OPTION AND LICENSE AGREEMENT This Agreement Is Entered Into With Effect as of the Effective Date (As Defined Below) by and Between (May 24th, 2018)

CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH [***]. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Knight Knox Development Corp. – Material and Data Transfer, Option and License Agreement (May 14th, 2018)

THIS MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT (this "Agreement") entered into on this December 20, 2017 (the "Signature Date") by and between NEOMED Institute, a not-for-profit corporation established under the Not-for-Profit Corporations Act (Canada), having an address at 7171 Frederick-Banting, Saint-Laurent, Quebec H4S 1Z9, Canada ("NEOMED"), and Artelo Biosciences, Inc., a Nevada corporation, having an address at 888 Prospect Street, Suite 210, La Jolla, California 92037, U.S.A. ("Artelo") shall be effective as of the Effective Date (as defined in Section 1.9 below). Each of NEOMED and Artelo may be referred to herein as a "Party", or jointly as the "Parties".

Scholar Rock Holding Corp – [***] Indicates Material That Has Been Omitted and for Which Confidential Treatment Has Been Requested. All Such Omitted Material Has Been Filed With the Securities and Exchange Commission Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended Option and License Agreement by and Between Scholar Rock, Inc. And Janssen Biotech, Inc. Dated as of December 17, 2013 (April 27th, 2018)

THIS OPTION AND LICENSE AGREEMENT (this Agreement) is dated as of December 17, 2013 (the Effective Date) by and between Scholar Rock, Inc., a Delaware company having its principal place of business at 300 Third St., 4th Floor, Cambridge, MA 02142 (Scholar Rock), and Janssen Biotech, Inc., a Pennsylvania corporation having its principal place of business at 800/850 Ridgeview Drive, Horsham, PA 19044 (JBI). Scholar Rock and JBI are sometimes referred to herein individually as a Party and collectively as the Parties.

Scholar Rock Holding Corp – [***] Indicates Material That Has Been Omitted and for Which Confidential Treatment Has Been Requested. All Such Omitted Material Has Been Filed With the Securities and Exchange Commission Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended Option and License Agreement by and Between Scholar Rock, Inc. And Janssen Biotech, Inc. Dated as of December 17, 2013 (April 20th, 2018)

THIS OPTION AND LICENSE AGREEMENT (this Agreement) is dated as of December 17, 2013 (the Effective Date) by and between Scholar Rock, Inc., a Delaware company having its principal place of business at 300 Third St., 4th Floor, Cambridge, MA 02142 (Scholar Rock), and Janssen Biotech, Inc., a Pennsylvania corporation having its principal place of business at 800/850 Ridgeview Drive, Horsham, PA 19044 (JBI). Scholar Rock and JBI are sometimes referred to herein individually as a Party and collectively as the Parties.

Magenta Therapeutics, Inc. – EXCLUSIVE RESEARCH, DEVELOPMENT OPTION AND LICENSE AGREEMENT This Agreement Is Entered Into With Effect as of the Effective Date (As Defined Below) by and Between (March 28th, 2018)

CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH [***]. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Knight Knox Development Corp. – Material and Data Transfer, Option and License Agreement (March 21st, 2018)

THIS MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT (this "Agreement") entered into on this December 20, 2017 (the "Signature Date") by and between NEOMED Institute, a not-for-profit corporation established under the Not-for-Profit Corporations Act (Canada), having an address at 7171 Frederick-Banting, Saint-Laurent, Quebec H4S 1Z9, Canada ("NEOMED"), and Artelo Biosciences, Inc., a Nevada corporation, having an address at 888 Prospect Street, Suite 210, La Jolla, California 92037, U.S.A. ("Artelo") shall be effective as of the Effective Date (as defined in Section 1.9 below). Each of NEOMED and Artelo may be referred to herein as a "Party", or jointly as the "Parties".

GLOBAL DEVELOPMENT, OPTION AND LICENSE AGREEMENT Between NESTEC LTD. And CODEXIS, INC. (March 15th, 2018)

This GLOBAL DEVELOPMENT, OPTION AND LICENSE AGREEMENT (this "Agreement") is made as of October 12, 2017 (the "Effective Date"), by and between NESTEC LTD., a limited company organized and existing under the laws of Switzerland, having an office located at Avenue Nestle 55, 1800 Vevey, Switzerland ("NHSc"), and CODEXIS, INC., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 200 Penobscot Drive, Redwood City, CA 94063, USA ("Codexis"). NHSc and Codexis are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Avalanche Biotechnologies, Inc. – Amendment to Collaboration, Option and License Agreement (March 6th, 2018)

This Amendment ("Amendment") is entered into as of January 25, 2018 (the "Amendment Effective Date"), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O'Brien Drive, Menlo Park, CA 94025 ("Adverum"), and Editas Medicine, Inc., a Delaware corporation having an address at 11 Hurley St., Cambridge, MA 02141 ("Editas") and amends that certain Collaboration, Option and License Agreement, dated August 8, 2016, by and between Adverum and Editas (the "Agreement"). Adverum and Editas may be referred to herein individually as a "Party" and collectively as the "Parties."

Isis Pharmaceuticals, Inc. – Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc. And Biogen MA Inc. (February 28th, 2018)

This AMENDED AND RESTATED STRATEGIC NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into as of the 20th day of October, 2017 (the "Amendment Date") by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 ("Ionis"), and Biogen MA Inc., a Massachusetts corporation, having its principal place of business at 14 Cambridge Center, Cambridge, MA 02142 ("Biogen"). Biogen and Ionis each may be referred to herein individually as a "Party" or collectively as the "Parties." Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.

Isis Pharmaceuticals, Inc. – Research Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc. And Biogen MA Inc. (February 28th, 2018)

This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (this "Agreement") is entered into as of the 19th day of December 2017 (the "Effective Date") by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 ("Ionis"), and Biogen MA Inc., a Massachusetts corporation, having its principal place of business at 225 Binney Street, Cambridge, MA 02142 ("Biogen"). Biogen and Ionis each may be referred to herein individually as a "Party" or collectively as the "Parties." Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.

Ultragenyx Pharmaceutical Inc. – Option and License Agreement (February 21st, 2018)

This OPTION AND LICENSE AGREEMENT ("Agreement") is entered into as of March 10, 2015 (the "Execution Date"), with effectiveness as of February 18, 2014 (the "Effective Date"), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 ("Licensor"), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 ("Licensee"). Licensor and Licensee are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Arcus Biosciences, Inc. – Confidential Treatment Requested Option and License Agreement (February 16th, 2018)

THIS OPTION AND LICENSE AGREEMENT (Agreement) is made and entered into effective as of September 19, 2017 (the Effective Date), by and between ARCUS BIOSCIENCES, INC., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (Arcus), and TAIHO PHARMACEUTICAL CO., LTD., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (TAIHO).

To the Strategic Collaboration, Option and License Agreement (February 15th, 2018)

This Amendment No. 1 to the Strategic Collaboration, Option and License Agreement, dated October 26, 2015, between Vertex Pharmaceuticals Incorporated (" Vertex Parent ") and Vertex Pharmaceuticals (Europe) Limited (" Vertex UK " and together with Vertex Parent, " Vertex "), on the one hand, and CRISPR Therapeutics AG (" CRISPR AG "), CRISPR Therapeutics, Inc. (" CRISPR Inc. "), CRISPR Therapeutics Limited (" CRISPR UK ") and TRACR Hematology Ltd (" Tracr " and together with CRISPR AG, CRISPR Inc. and CRISPR UK " CRISPR "), on the other hand (this " Amendment ") is entered into as of this 12th day of December, 2017 (the " Amendment Effective Date ") by and between Vertex and CRISPR. Capitalized terms used and not defined herein have their respective meanings set forth in the Agreement (as defined below).

Arcus Biosciences, Inc. – Confidential Treatment Requested Option and License Agreement (January 19th, 2018)

THIS OPTION AND LICENSE AGREEMENT (Agreement) is made and entered into effective as of September 19, 2017 (the Effective Date), by and between ARCUS BIOSCIENCES, INC., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (Arcus), and TAIHO PHARMACEUTICAL CO., LTD., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (TAIHO).

Knight Knox Development Corp. – Confidential Treatment Requested Confidential Portions of This Document Have Been Redacted and Have Been Separately Filed With the Securities and Exchange Commission. Information That Was Omitted in the Edgar Version Has Been Noted in This Document With a Placeholder Identified by the Mark "[***]". Material and Data Transfer, Option and License Agreement (January 16th, 2018)

THIS MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT (this "Agreement") entered into on this December 20, 2017 (the "Signature Date") by and between NEOMED Institute, a not-for-profit corporation established under the Not-for-Profit Corporations Act (Canada), having an address at 7171 Frederick-Banting, Saint-Laurent, Quebec H4S 1Z9, Canada ("NEOMED"), and Artelo Biosciences, Inc., a Nevada corporation, having an address at 888 Prospect Street, Suite 210, La Jolla, California 92037, U.S.A. ("Artelo") shall be effective as of the Effective Date (as defined in Section 1.9 below). Each of NEOMED and Artelo may be referred to herein as a "Party", or jointly as the "Parties".

Knight Knox Development Corp. – Material and Data Transfer, Option and License Agreement (December 22nd, 2017)

THIS MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT (this "Agreement") entered into on this December 20, 2017 (the "Signature Date") by and between NEOMED Institute, a not-for-profit corporation established under the Not-for-Profit Corporations Act (Canada), having an address at 7171 Frederick-Banting, Saint-Laurent, Quebec H4S 1Z9, Canada ("NEOMED"), and Artelo Biosciences, Inc., a Nevada corporation, having an address at 888 Prospect Street, Suite 210, La Jolla, California 92037, U.S.A. ("Artelo") shall be effective as of the Effective Date (as defined in Section 1.9 below). Each of NEOMED and Artelo may be referred to herein as a "Party", or jointly as the "Parties".

CRISPR Therapeutics AG – Amendment No. 1 to the Strategic Collaboration, Option and License Agreement (December 18th, 2017)

This Amendment No. 1 to the Strategic Collaboration, Option and License Agreement, dated October 26, 2015, between Vertex Pharmaceuticals Incorporated (Vertex Parent) and Vertex Pharmaceuticals (Europe) Limited (Vertex UK and together with Vertex Parent, Vertex), on the one hand, and CRISPR Therapeutics AG (CRISPR AG), CRISPR Therapeutics, Inc. (CRISPR Inc.), CRISPR Therapeutics Limited (CRISPR UK) and TRACR Hematology Ltd (Tracr and together with CRISPR AG, CRISPR Inc. and CRISPR UK CRISPR), on the other hand (this Amendment) is entered into as of this 12th day of December, 2017 (the Amendment Effective Date) by and between Vertex and CRISPR. Capitalized terms used and not defined herein have their respective meanings set forth in the Agreement (as defined below).

Arcus Biosciences, Inc. – Confidential Treatment Requested Option and License Agreement (December 15th, 2017)

THIS OPTION AND LICENSE AGREEMENT (Agreement) is made and entered into effective as of September 19, 2017 (the Effective Date), by and between ARCUS BIOSCIENCES, INC., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (Arcus), and TAIHO PHARMACEUTICAL CO., LTD., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (TAIHO).

Monopar Therapeutics – VALIDIVE(r) OPTION AND LICENSE AGREEMENT BY AND BETWEEN MONOPAR THERAPEUTICS INC. And (November 9th, 2017)

THIS OPTION AND LICENSE AGREEMENT (together with any Schedules attached hereto, this "Agreement") is made and entered into as of June 17, 2016 (the "Effective Date"), by and between Monopar Therapeutics Inc., a Delaware corporation located at 598 Rockefeller Rd, Lake Forest, Illinois 60201, United States of America ("Monopar"), and Onxeo S.A., a French societe anonyme a Conseil d'administration located at 49, boulevard du General Martial Valin, 75015 Paris, France ("Onxeo"). Monopar and Onxeo are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Max-1 Acquisition Corp – RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and Between EXICURE, INC. And PURDUE PHARMA L.P. (November 7th, 2017)

This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (this "Agreement") is entered into as of December 2nd, 2016 (the "Effective Date") by and between EXICURE, INC., a Delaware corporation having an address at 8045 Lamon Ave, Skokie, Illinois 60077, United States of America ("Licensor"), and PURDUE PHARMA L.P., a Delaware limited partnership having an address at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901, United States of America ("Licensee"). Licensor and Licensee are sometimes referred to individually as a "Party" and collectively as the "Parties."

Arsanis, Inc. – Option and License Agreement (October 20th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Arsanis, Inc. – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. AMENDMENT NO. 1 to the OPTION AND LICENSE AGREEMENT (October 20th, 2017)
Arsanis, Inc. – Option and License Agreement (September 20th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Arsanis, Inc. – Option and License Agreement (August 10th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Isis Pharmaceuticals, Inc. – Strategic Collaboration, Option and License Agreement (May 9th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into as of the 5th day of January, 2017 (the "Execution Date") by and between Akcea Therapeutics, Inc., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akcea's Affiliates ("Akcea"), andNovartis Pharma AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland ("Novartis"). Novartis and Akcea each may be referred to herein individually as a "Party" or collectively as the "Parties." Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. ("Ionis") and therefore Akcea and Ionis are Affiliates.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (April 10th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Avalanche Biotechnologies, Inc. – Collaboration, Option and License Agreement (April 5th, 2017)

THIS COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of August 8, 2016 (Effective Date), by and between ADVERUM BIOTECHNOLOGIES, INC., a Delaware corporation having an address at 1035 OBrien Drive, Menlo Park, CA 94025 (Adverum), and EDITAS MEDICINE, INC., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 (Editas). Adverum and Editas may be referred to herein individually as a Party and collectively as the Parties.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (March 27th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Chimerix Inc. – Patent Option and License Agreement (March 2nd, 2017)

This Agreement is entered into on May 24, 2006 ("EFFECTIVE DATE"), between The Regents of the University of Michigan, a constitutional corporation of the State of Michigan ("MICHIGAN") located at Office of Technology Transfer, 3003 S. State Street, Suite 2071, Ann Arbor, MI 48109-1280, and Chimerix, Inc., a Delaware corporation ("COMPANY"), located at 5007 Southpark Drive, Suite 200, Durham, NC 27713.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (February 13th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Ocular Therapeutix, Inc – Collaboration, Option and License Agreement Between Ocular Therapeutix, Inc. And Regeneron Pharmaceuticals, Inc. (November 9th, 2016)

THIS COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is made and entered into, effective as of October 10, 2016 (the Effective Date), by and between Ocular Therapeutix, Inc., a corporation organized under the laws of Delaware and having an address at 36 Crosby Drive, Suite 101, Bedford, Massachusetts 01730 (Collaborator), and Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York and having an address at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (Regeneron). Collaborator and Regeneron are sometimes referred to herein individually as a Party and collectively as the Parties.

Avalanche Biotechnologies, Inc. – Collaboration, Option and License Agreement (November 8th, 2016)

This Collaboration, Option and License Agreement (the "Agreement") is entered into as of August 8, 2016 ("Effective Date"), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O'Brien Drive, Menlo Park, CA 94025 ("Adverum"), and Editas Medicine, Inc., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 ("Editas"). Adverum and Editas may be referred to herein individually as a "Party" and collectively as the "Parties."